How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience

How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience

Bibliographic Details
Main Author:	Piet L.C.M. van Riel
Format:	Article
Language:	English
Published:	PCO Convin S.A. 2016-01-01
Series:	Mediterranean Journal of Rheumatology
Subjects:	rheumatoid arthritis dmards csdmards bdmards biosimilars tapering biological treatment remission
Online Access:	https://www.mjrheum.org/assets/files/792/file35_992.pdf

Similar Items

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort
by: Stéphanie Dierckx, et al.
Published: (2020-04-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
by: Matthijs S. van der Leeuw, et al.
Published: (2020-04-01)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
by: Findeisen KE, et al.
Published: (2021-08-01)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
by: Fiona Rayner, et al.
Published: (2021-07-01)

Sustained drug-free remission and persistent hypogammaglobulinemia in a patient with rheumatoid arthritis three years after discontinuing Rituximab treatment
by: Marco Krasselt, et al.
Published: (2021-04-01)

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
by: José A. Sacristán, et al.
Published: (2019-10-01)

Patterns of Response to Different Treatment Strategies in Seropositive Rheumatoid Arthritis Patients in a Tertiary Hospital in South‐Western Saudi Arabia: A Retrospective Study
by: AlOmair M, et al.
Published: (2021-08-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
by: Hiroki Tawaratsumida, et al.
Published: (2017-12-01)

“Living a normal life”: a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis
by: Kenneth F. Baker, et al.
Published: (2019-06-01)

ASSOCIATION OF SEROLOGICAL STATUS WITH THE FREQUENCY OF CLINICAL AND RADIOLOGICAL REMISSION IN RHEUMATOID ARTHRITIS
by: O.B. Iaremenko
Published: (2021-06-01)

Disease Modifying Anti-Rheumatic Drugs: Review on Pregnancy and Lactation
by: Tsz-Yuen wu, et al.
Published: (2019-07-01)

Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt
by: Joao Lagoas Gomes, et al.
Published: (2019-01-01)

Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs
by: Lurati A, et al.
Published: (2021-04-01)

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
by: Eleni Kampylafka, et al.
Published: (2018-07-01)

Rheumatoid arthritis
by: Yoshiya Tanaka
Published: (2020-09-01)

Management of rheumatoid arthritis during pregnancy: challenges and solutions
by: Krause ML, et al.
Published: (2016-03-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

The importance of early arthritis in patients with rheumatoid arthritis
by: Georgiana Iftimie, et al.
Published: (2018-10-01)

Rheumatoid arthritis and lymphoma: the role of disease-modifying anti-rheumatic drugs
by: Detrick, Jordan
Published: (2018)

A Systematic Review to Identify the Effects of Biologics in the Feet of Patients with Rheumatoid Arthritis
by: Laura Ramos-Petersen, et al.
Published: (2021-12-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
by: Debbie M. Boeters, et al.
Published: (2019-05-01)

Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis
by: Leon G. D’Cruz, et al.
Published: (2020-09-01)

IL-6 but Not TNFα Levels Are Associated With Time to Pregnancy in Female Rheumatoid Arthritis Patients With a Wish to Conceive
by: Margot Bongenaar, et al.
Published: (2020-12-01)

Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
by: Hiroto Tokumoto, et al.
Published: (2018-02-01)

Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
by: Chayma Ladhari, et al.
Published: (2020-02-01)

The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study)
by: Bambang Setyohadi, et al.
Published: (2018-06-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
by: Akhlaghi S, et al.
Published: (2018-10-01)

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
by: Yannick Degboé, et al.
Published: (2020-06-01)

Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study
by: Theofanis Karageorgas, et al.
Published: (2018-01-01)